Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA v. HHS

Executive Summary

Michigan Medicaid supplemental rebate program upheld by D.C. federal court March 28. The court heard oral arguments on the Pharmaceutical Research & Manufacturers of America's challenge of the program Aug. 28, 2002 and Feb. 5 (1"The Pink Sheet" Feb. 10, p. 16)...

You may also be interested in...



Michigan Rx rebate requirements upheld

Michigan Medicaid may require prior authorization for drugs that do not provide rebates to non-Medicaid programs, D.C. federal appeals court affirms April 2. The Pharmaceutical Research & Manufacturers of America's lawsuit against the state argued the policy was not in the "best interest" of Medicaid recipients; the lower court also ruled against PhRMA (1"The Pink Sheet" March 31, 2003, In Brief). The 2appellate court ruling cited the Supreme Court's rejection of PhRMA's challenge to a similar Maine program last year (3"The Pink Sheet" May 26, 2003, p. 23). [Editor's Note: A version of this story first appeared in 4"The Pink Sheet" DAILY April 2. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]...

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

UsernamePublicRestriction

Register

PS041539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel